Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SILO PharmaSILO 42 Market Cap is $3.68 Mil as of Sep. 11, 2026. GuruFocus rates SILO with a GF Score™ of 42/100 and a GF Value™ of $3.44 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,421 Biotechnology companies, SILO Pharma ranks worse than 92.96% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SILO Pharma's share price for the quarter that ended in Jun. 2026 was $6.21. SILO Pharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 1.13 Mil. Therefore, SILO Pharma's market cap for the quarter that ended in Jun. 2026 was $7.01 Mil.
SILO Pharma's quarterly market cap
increased
from Dec. 2025 ($4.53 Mil) to Mar. 2026 ($5.85 Mil) and
increased
from Mar. 2026 ($5.85 Mil) to Jun. 2026 ($7.01 Mil).
SILO Pharma's annual market cap
declined
from Dec. 2023 ($4.19 Mil) to Dec. 2024 ($3.99 Mil) but then
increased
from Dec. 2024 ($3.99 Mil) to Dec. 2025 ($4.53 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SILO Pharma's Enterprise Value for Today is $-1.75 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SILO Pharma Market Cap Related Terms
SILO Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for SILO Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SILO Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SILO Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SILO Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where SILO Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SILO Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SILO Pharma (SILO) has a Market Cap of $3.68 Mil as of Sep. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SILO Pharma and its competitors. According to the industry distribution chart, SILO Pharma ranks #1321 out of 1421 companies in the Biotechnology industry, placing it in the top 93%.
Is SILO Pharma's Market Cap too high?
SILO Pharma's current Market Cap is $3.68 Mil. The Biotechnology industry median Market Cap is 118.46. SILO Pharma's value of $3.68 Mil is 96.9% below this industry median. Based on the distribution chart, SILO Pharma ranks #1321 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SILO Pharma has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SILO Pharma's Market Cap compare to ELAB and GLMD?
According to the Biotechnology industry distribution chart, SILO Pharma ranks #1321 out of 1421 companies for Market Cap. This places SILO Pharma in the lower half of its industry. The industry median Market Cap is 118.46. SILO Pharma's value of $3.68 Mil is 96.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 118.46, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SILO Pharma's current Market Cap of $3.68 Mil is 96.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SILO Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 118.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SILO Pharma's current Market Cap is $3.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SILO Pharma stock overvalued right now?
Based on GuruFocus' analysis, SILO Pharma (SILO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.44, compared to a current price of $2.10 — trading 39% below its estimated fair value. The current Market Cap is $3.68 Mil and 96.9% below the Biotechnology industry median of 118.46. SILO Pharma's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SILO Pharma (SILO), the current Market Cap is $3.68 Mil as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SILO Pharma (SILO) Overvalued in 2026?
Based on GuruFocus' analysis, SILO Pharma stock appears to be undervalued.
The current stock price of $2.10 is trading 39% below its estimated GF Value™ of $3.44.
GuruFocus considers SILO Pharma to be Possible Value Trap.
Key valuation signals for SILO:
Market Cap: $3.68 Mil
GF Value™: $3.44 vs. price of $2.10 (39% below fair value)
Industry Position: 96.9% below the Biotechnology median (#1321 of 1421)
No single metric tells the full story. See the SILO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
42GF Score
Get the complete analysis for SILO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SILO has been successfully added to your 
